Cargando…

PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers

Introduction: Frontotemporal lobar degeneration (FTLD)-related syndrome includes progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). PSP is usually caused by a tauopathy but can have associated Alzheimer's disease (AD) while CBS can be caused by tauopathy, transactive response...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasilevskaya, Anna, Taghdiri, Foad, Multani, Namita, Anor, Cassandra, Misquitta, Karen, Houle, Sylvain, Burke, Charles, Tang-Wai, David, Lang, Anthony E., Fox, Susan, Slow, Elizabeth, Rusjan, Pablo, Tartaglia, Maria C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366127/
https://www.ncbi.nlm.nih.gov/pubmed/32754109
http://dx.doi.org/10.3389/fneur.2020.00574
_version_ 1783560169098051584
author Vasilevskaya, Anna
Taghdiri, Foad
Multani, Namita
Anor, Cassandra
Misquitta, Karen
Houle, Sylvain
Burke, Charles
Tang-Wai, David
Lang, Anthony E.
Fox, Susan
Slow, Elizabeth
Rusjan, Pablo
Tartaglia, Maria C.
author_facet Vasilevskaya, Anna
Taghdiri, Foad
Multani, Namita
Anor, Cassandra
Misquitta, Karen
Houle, Sylvain
Burke, Charles
Tang-Wai, David
Lang, Anthony E.
Fox, Susan
Slow, Elizabeth
Rusjan, Pablo
Tartaglia, Maria C.
author_sort Vasilevskaya, Anna
collection PubMed
description Introduction: Frontotemporal lobar degeneration (FTLD)-related syndrome includes progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). PSP is usually caused by a tauopathy but can have associated Alzheimer's disease (AD) while CBS can be caused by tauopathy, transactive response DNA binding protein 43 kDa, or AD pathology. Our aim was to compare the parkinsonian syndromes presenting without AD biomarkers (CBS/PSP-non-AD) to parkinsonian syndromes with AD biomarkers (CBS/PSP-AD). Materials and Methods: Twenty-four patients [11 males, 13 females; age (68.46 ± 7.23)] were recruited for this study. The whole cohort was divided into parkinsonian syndromes without AD biomarkers [N = 17; diagnoses (6 CBS, 11 PSP)] and parkinsonian syndromes with AD biomarkers [N = 7; diagnoses (6 CBS-AD, 1 PSP-AD)]. Anatomical MRI and PET imaging with tau ligand [18F]-AV1451 tracer was completed. Cerebrospinal fluid analysis or [18F]-AV1451 PET imaging was used to assess for the presence of AD biomarkers. Progressive supranuclear palsy rating scale (PSPRS) and unified Parkinson's disease rating scale (UPDRS) motor exam were implemented to assess for motor disturbances. Language and cognitive testing were completed. Results: The CBS/PSP-non-AD group [age (70.18 ± 6.65)] was significantly older (p = 0.028) than the CBS/PSP-AD group [age (64.29 ± 7.32)]. There were no differences between the groups in terms of gender, education, years of disease duration, and disease severity as measured with the Clinical Dementia Rating scale. The CBS/PSP-non-AD group had significantly lower PET Tau Standard Volume Uptake Ratio (SUVR) values compared to the CBS/PSP-AD group in multiple frontal and temporal areas, and inferior parietal (all p < 0.03). The CBS/PSP-non-AD group had significantly higher scores compared to the CBS/PSP-AD group on PSPRS (p = 0.004) and UPDRS motor exam (p = 0.045). The CBS/PSP-non-AD group had higher volumes of inferior parietal, precuneus, and hippocampus (all p < 0.02), but lower volume of midbrain (p = 0.02), compared to the CBS/PSP-AD group. Discussion: The CBS/PSP-non-AD group had higher motor disturbances compared to the CBS/PSP-AD group; however, both groups performed similarly on neuropsychological measures. The AD biomarker group had increased global uptake of PET Tau SUVR and lower volumes in AD-specific areas. These results show that the presenting phenotype of CBS and PSP syndromes and the distribution of injury are strongly affected by the presence of AD biomarkers.
format Online
Article
Text
id pubmed-7366127
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73661272020-08-03 PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers Vasilevskaya, Anna Taghdiri, Foad Multani, Namita Anor, Cassandra Misquitta, Karen Houle, Sylvain Burke, Charles Tang-Wai, David Lang, Anthony E. Fox, Susan Slow, Elizabeth Rusjan, Pablo Tartaglia, Maria C. Front Neurol Neurology Introduction: Frontotemporal lobar degeneration (FTLD)-related syndrome includes progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). PSP is usually caused by a tauopathy but can have associated Alzheimer's disease (AD) while CBS can be caused by tauopathy, transactive response DNA binding protein 43 kDa, or AD pathology. Our aim was to compare the parkinsonian syndromes presenting without AD biomarkers (CBS/PSP-non-AD) to parkinsonian syndromes with AD biomarkers (CBS/PSP-AD). Materials and Methods: Twenty-four patients [11 males, 13 females; age (68.46 ± 7.23)] were recruited for this study. The whole cohort was divided into parkinsonian syndromes without AD biomarkers [N = 17; diagnoses (6 CBS, 11 PSP)] and parkinsonian syndromes with AD biomarkers [N = 7; diagnoses (6 CBS-AD, 1 PSP-AD)]. Anatomical MRI and PET imaging with tau ligand [18F]-AV1451 tracer was completed. Cerebrospinal fluid analysis or [18F]-AV1451 PET imaging was used to assess for the presence of AD biomarkers. Progressive supranuclear palsy rating scale (PSPRS) and unified Parkinson's disease rating scale (UPDRS) motor exam were implemented to assess for motor disturbances. Language and cognitive testing were completed. Results: The CBS/PSP-non-AD group [age (70.18 ± 6.65)] was significantly older (p = 0.028) than the CBS/PSP-AD group [age (64.29 ± 7.32)]. There were no differences between the groups in terms of gender, education, years of disease duration, and disease severity as measured with the Clinical Dementia Rating scale. The CBS/PSP-non-AD group had significantly lower PET Tau Standard Volume Uptake Ratio (SUVR) values compared to the CBS/PSP-AD group in multiple frontal and temporal areas, and inferior parietal (all p < 0.03). The CBS/PSP-non-AD group had significantly higher scores compared to the CBS/PSP-AD group on PSPRS (p = 0.004) and UPDRS motor exam (p = 0.045). The CBS/PSP-non-AD group had higher volumes of inferior parietal, precuneus, and hippocampus (all p < 0.02), but lower volume of midbrain (p = 0.02), compared to the CBS/PSP-AD group. Discussion: The CBS/PSP-non-AD group had higher motor disturbances compared to the CBS/PSP-AD group; however, both groups performed similarly on neuropsychological measures. The AD biomarker group had increased global uptake of PET Tau SUVR and lower volumes in AD-specific areas. These results show that the presenting phenotype of CBS and PSP syndromes and the distribution of injury are strongly affected by the presence of AD biomarkers. Frontiers Media S.A. 2020-07-10 /pmc/articles/PMC7366127/ /pubmed/32754109 http://dx.doi.org/10.3389/fneur.2020.00574 Text en Copyright © 2020 Vasilevskaya, Taghdiri, Multani, Anor, Misquitta, Houle, Burke, Tang-Wai, Lang, Fox, Slow, Rusjan and Tartaglia. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Vasilevskaya, Anna
Taghdiri, Foad
Multani, Namita
Anor, Cassandra
Misquitta, Karen
Houle, Sylvain
Burke, Charles
Tang-Wai, David
Lang, Anthony E.
Fox, Susan
Slow, Elizabeth
Rusjan, Pablo
Tartaglia, Maria C.
PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
title PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
title_full PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
title_fullStr PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
title_full_unstemmed PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
title_short PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers
title_sort pet tau imaging and motor impairments differ between corticobasal syndrome and progressive supranuclear palsy with and without alzheimer's disease biomarkers
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366127/
https://www.ncbi.nlm.nih.gov/pubmed/32754109
http://dx.doi.org/10.3389/fneur.2020.00574
work_keys_str_mv AT vasilevskayaanna pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT taghdirifoad pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT multaninamita pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT anorcassandra pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT misquittakaren pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT houlesylvain pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT burkecharles pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT tangwaidavid pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT langanthonye pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT foxsusan pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT slowelizabeth pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT rusjanpablo pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers
AT tartagliamariac pettauimagingandmotorimpairmentsdifferbetweencorticobasalsyndromeandprogressivesupranuclearpalsywithandwithoutalzheimersdiseasebiomarkers